ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is among the 13 Biotech Stocks with Huge Upside Potential. It declared that the U.S ...

Acadia Pharmaceuticals said on Monday that the U.S. Court of Appeals has confirmed the validity of its patent for Nuplazid, ...

Acadia Pharmaceuticals has scored a second court win in less than a month that protects patents for its Parkinson's Disease treatment Nuplazid. The biopharmaceutical company said Monday that a federal ...

Acadia Pharmaceuticals (NASDAQ: ACAD) announced that the U.S. Court of Appeals has upheld the validity of its patent for ...

The FDA Commissioner Marty Makary stated the FDA will reach its 2025 drug approval targets despite severe workforce ...

US Court of Appeals upholds Acadia Pharmaceuticals' patent for Nuplazid, securing protection against generic competition ...

SAN DIEGO, June 09, 2025--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Court of Appeals for the Federal Circuit affirmed a decision issued by the U.S. District Court for ...

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United ...

In a report released today, Joel Beatty from Robert W. Baird maintained a Buy rating on Axsome Therapeutics ( AXSM – Research Report ), with a price target of $157.00. The company’s shares opened ...